The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study-Reference-Cited by-同舟云学术

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study

Published:2019-07 Issue:10193 Volume:394 Page:148-158
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Van Damme Pierre,De Coster Ilse,Bandyopadhyay Ananda S,Revets Hilde,Withanage Kanchanamala,De Smedt Philippe,Suykens Leen,Oberste M Steven,Weldon William C,Costa-Clemens Sue Ann,Clemens Ralf,Modlin John,Weiner Amy J,Macadam Andrew J,Andino Raul,Kew Olen M,Konopka-Anstadt Jennifer L,Burns Cara C,Konz John,Wahid Rahnuma,Gast Christopher

Funder

Bill and Melinda Gates Foundation

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Progress toward containment of poliovirus type 2—worldwide, 2017;Previsani;MMWR Morb Mortal Wkly Rep,2017

2. Poliovirus vaccine-live;Sutter,2012

3. Fighting a polio outbreak in Papua New Guinea;Chandler;Lancet,2018

4. Update on vaccine-derived polioviruses—worldwide, January 2017–June 2018;Jorba;MMWR Morb Mortal Wkly Rep,2018

5. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine;Duintjer Tebbens;Expert Rev Vaccines,2018

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Excretion in an Infant with Severe Combined Immune Deficiency with Spillover to a Parent;Vaccines;2024-07-09

2. Detection of Polioviruses Type 2 among Migrant Children Arriving to the Russian Federation from a Country with a Registered Poliomyelitis Outbreak;Vaccines;2024-06-28

3. Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review;Pharmaceuticals;2024-06-19

4. Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study;The Lancet Infectious Diseases;2024-04

5. Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022;Emerging Infectious Diseases;2024-04